Lentiviral vectors targeting KRAS neoepitopes for cancer immunotherapy

Abstract

It further relates to lentiviral vector particle, an isolated cell or a pharmaceutical composition comprising a lentiviral vector according to the invention. The invention further provides a combinatory treatment comprising at least one lentiviral vector, a lentiviral vector particle, an isolated cell or a pharmaceutical composition according to the invention, and at least one chemotherapy agent or treatment and / or at least one immunotherapy agent or treatment. Finally, the invention provides any of the above for their use in the treatment and / or prevention of cancers, in particular of cancers wherein the KRAS1-23 N-terminal segment is mutated.

Images